PMID- 28915618
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20170925
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 34
DP  - 2017 Aug 22
TI  - Suppression of miR-16 promotes tumor growth and metastasis through reversely 
      regulating YAP1 in human cholangiocarcinoma.
PG  - 56635-56650
LID - 10.18632/oncotarget.17832 [doi]
AB  - BACKGROUND & AIMS: Aberrant expression of microRNAs is associated with many 
      cancers progression. Many studies have shown that miR-16 is down-regulated in 
      many cancers. However, its role in cholangiocarcinoma (CCA) is unknown. METHODS: 
      Quantitative real-time PCR (qRT-PCR) was developed to measure miR-16 expression 
      in CCA tissues and cell lines. CCK-8, colony formation and transwell assays were 
      used to reveal the role of miR-16 in CCA cell proliferation and malignant 
      transformation in vitro. The loss-and-gain function was further validated by 
      subcutaneous xenotransplantation and tail vein injection xenotransplantation 
      model in vivo. Dual-luciferase reporter assay was performed to validate the 
      relationship of miR-16 with YAP1. RESULTS: MiR-16 was notably downregulated in 
      CCA tissues, which was associated with tumor size, metastasis, and TNM stage. 
      Both in vitro and in vivo studies demonstrated that miR-16 could suppress 
      proliferation, invasion and metastasis throughout the progression of CCA. We 
      further identified YAP1 as a direct target gene of miR-16 and found that miR-16 
      could regulate CCA cell growth and invasion in a YAP1-dependent manner. In 
      addition, YAP1 was markedly upregulated in CCA tissues, which was reversely 
      correlated with miR-16 level in tissue samples. Besides, Down-regulation of 
      miR-16 was remarkably associated with tumor progression and poor survival in CCA 
      patients through a Kaplan-Meier survival analysis. CONCLUSIONS: miR-16, as a 
      novel tumor suppressor in CCA through directly targeting YAP1, might be a 
      promising therapeutic target or prognosis biomarker for CCA.
FAU - Han, Sheng
AU  - Han S
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Wang, Dong
AU  - Wang D
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Tang, Guohua
AU  - Tang G
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Yang, Xinxiang
AU  - Yang X
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Jiao, Chenyu
AU  - Jiao C
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Yang, Renjie
AU  - Yang R
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Zhang, Yaodong
AU  - Zhang Y
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Huo, Liqun
AU  - Huo L
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Shao, Zicheng
AU  - Shao Z
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Lu, Zefa
AU  - Lu Z
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Zhang, Jiawei
AU  - Zhang J
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
FAU - Li, Xiangcheng
AU  - Li X
AD  - Liver Transplantation Center of The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu Province, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170512
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5593589
OTO - NOTNLM
OT  - CCA
OT  - metastasis
OT  - miRNA
OT  - prognosis
OT  - proliferation
COIS- CONFLICTS OF INTEREST The authors declare that they have no financial conflicts 
      of interest.
EDAT- 2017/09/17 06:00
MHDA- 2017/09/17 06:01
PMCR- 2017/08/22
CRDT- 2017/09/17 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/04/19 00:00 [accepted]
PHST- 2017/09/17 06:00 [entrez]
PHST- 2017/09/17 06:00 [pubmed]
PHST- 2017/09/17 06:01 [medline]
PHST- 2017/08/22 00:00 [pmc-release]
AID - 17832 [pii]
AID - 10.18632/oncotarget.17832 [doi]
PST - epublish
SO  - Oncotarget. 2017 May 12;8(34):56635-56650. doi: 10.18632/oncotarget.17832. 
      eCollection 2017 Aug 22.